而在此前不久，锦波生物控股股东、实际控制人杨霞已将其持有的575.33万股股票转让给杭州久视，占 公司总股本的5%，共计14.03亿元。据了解，养生堂与杭州久视的实控人均为钟睒睒。 21世纪经济报道记者韩利明 近期，北交所"重组胶原蛋白第一股"锦波生物公告显示，拟向养生堂发行不超过717.56万股股份，占发 行前公司总股本的6.24%，发行价格为278.72元/股，募资总额不超过20亿元，用于人源化胶原蛋白FAST 数据库与产品开发平台项目等。该申请已获北交所受理。 据《福布斯中国内地富豪榜》，2024年钟睒睒凭借508亿美元身家成功蝉联中国内地首富；进入2025 年，《福布斯全球亿万富豪榜》显示，其在内地富豪中的排名落于张一鸣之后。 值得关注的是，锦波生物是其继万泰生物（603392）后，再次重资投入的生物技术领域企业。在这背 后，万泰生物作为曾经风光无限的国产HPV疫苗头部企业，自2023年起业绩出现持续下滑，这也使得市 场对钟睒睒此次新入局的锦波生物及背后的医美赛道更为关注。 从行业大环境来看，近年来我国医美市场需求呈现旺盛且多元的发展态势，上游产品技术的迭代创新与 现有产品适应症的不断扩展，持续丰富着 ...

Core Viewpoint - The stock of Giant Bio has seen a significant increase, with a rise of over 5% in early trading, currently priced at 57.80 HKD, with a trading volume of 392 million HKD. The company reported a revenue of approximately 3.113 billion HKD for the first half of the year, reflecting a year-on-year growth of 22.5%, and a net profit attributable to shareholders of approximately 1.182 billion HKD, up 20.2% year-on-year [1]. Financial Performance - Giant Bio's revenue for the first half of the year is approximately 3.113 billion HKD, representing a year-on-year increase of 22.5% [1]. - The net profit attributable to the parent company is around 1.182 billion HKD, showing a year-on-year growth of 20.2% [1]. Analyst Insights - CICC maintains its profit forecast for Giant Bio at 2.5 billion HKD and 3.2 billion HKD for the years 2025 and 2026, respectively [1]. - The current stock price corresponds to a price-to-earnings (P/E) ratio of 21x and 17x for the years 2025 and 2026 [1]. - CICC has reiterated its "outperform" rating and target price of 82 HKD, indicating a potential upside of 50% based on a P/E ratio of 32x and 25x for the years 2025 and 2026 [1]. Market Outlook - With the Double Eleven shopping festival approaching, an increase in marketing frequency is expected to drive brand awareness and customer acquisition, potentially restoring growth momentum for the brand [1].

美银证券发布研报称，巨子生物(02367)上半年业绩略超预期，总收入31.13亿元人民币，同比增长 22.5%。该行基于上半年表现及今年7月强劲的线上表现，上调公司旗下品牌可复美(Comfy)的收入预 测，并将2025至2027年的总收入预测各上调1.9%。此外，因巨子生物的直播收入贡献降低，下调2025 年销售费用比率;将2025至207年每股盈利预测分别上调2%、1.7%及1.7%。对其目标价由79港元微升至 79.5港元，重申"买入"评级，因为重组胶原蛋白产品的增长可见度高。 ...

Core Insights - Jinbo Bio reported a significant increase in net profit for 2024, with a year-on-year growth of 144.27% [1] - The company's operating revenue reached 1.44 billion, marking an 84.92% increase compared to the previous year [1] - The gross profit margin improved to 92.02%, up by 1.86 percentage points from the previous year [2] Financial Performance - Operating revenue for 2024 was 1,442,831,399.69, compared to 780,260,212.25 in 2023, reflecting an 84.92% increase [1] - Net profit attributable to shareholders was 732,301,620.38, a 144.27% increase from 299,796,292.39 in 2023 [1] - The net profit after deducting non-recurring gains and losses was 712,180,480.92, up 149.15% from 285,842,673.17 in the previous year [1] - Basic earnings per share rose to 8.27, a 131.65% increase from 3.57 in 2023 [1] Cost and Expenses - Total period expenses for 2024 were 467 million, an increase of 114 million from the previous year [2] - The expense ratio decreased to 32.40%, down by 12.86 percentage points compared to the previous year [2] - Sales expenses increased by 56.73%, while management expenses rose by 38.08% [2] - Research and development expenses decreased by 16.20%, and financial expenses fell by 5.46% [2] Employee Statistics - The total number of employees increased to 823 in 2024, up from 730 in the previous year, representing a 13.29% growth [3] Leadership and Governance - The chairman of Jinbo Bio, Yang Xia, received a salary of 2.2 million in 2024, a decrease of 18.46% from 2.698 million in 2023 [4] - The company has a diverse leadership team with various educational backgrounds, including PhDs and master's degrees [3][5] Company Overview - Jinbo Bio, established on March 28, 2008, specializes in the research, production, and sales of medical devices and functional skincare products, focusing on recombinant collagen products and anti-HPV biological protein products [5]

Core Insights - Jinbo Bio announced two significant transactions, including a strategic investment from Yangshengtang, which involves issuing up to 7.1757 million shares, representing 6.24% of the pre-issue total share capital, to raise no more than 2 billion yuan, potentially marking the largest cash private placement in the history of the Beijing Stock Exchange [1] - The controlling shareholder Yang Xia signed a share transfer agreement with Hangzhou Jiushi, transferring 5.7533 million shares at a price of 243.84 yuan per share, totaling 1.403 billion yuan [4] - The ultimate controllers of both Yangshengtang and Hangzhou Jiushi are Zhong Shanshan, who has invested 3.4 billion yuan into Jinbo Bio [5] Financial Performance - Following Zhong Shanshan's investment, Jinbo Bio's stock price surged, with a total market capitalization exceeding 40.3 billion yuan, trading at 350.55 yuan, up 0.5% [7] - As of March 31, 2025, Jinbo Bio reported cash and cash equivalents of 959 million yuan, indicating a slight increase from 941 million yuan at the end of 2024 [10] Strategic Implications - The introduction of Yangshengtang as a strategic investor is expected to empower Jinbo Bio in various aspects, including product development, industrial production, commercialization, market strategy, and management, thereby addressing capacity construction and product commercialization challenges [10] - The collaboration signifies a notable shift in the competitive landscape of the medical aesthetics industry, with Jinbo Bio aiming to enhance its market position through this partnership [11]

Group 1 - Qiyunshan Food Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on June 27, aiming to expand its e-commerce network and enhance online promotion [1] - Qiyunshan holds a 32.4% market share in China's sour jujube food market, making it the industry leader [1] - The company plans to leverage its capital operations to increase brand influence and product value, although public awareness of sour jujube remains low [1] Group 2 - Jinbo Biological, a leading collagen company, disclosed a private placement plan to raise up to 2 billion yuan by issuing shares to Yangshengtang Co., Ltd. [2] - After the issuance, Yangshengtang will hold over 5% of Jinbo Biological, becoming its second-largest shareholder [2] - The collaboration is expected to enhance Jinbo Biological's brand promotion and product management, aligning well with Yangshengtang's anti-aging cosmetics focus [2] Group 3 - The China Consumers Association advocated against food waste and extreme eating broadcasts, emphasizing the importance of frugality and food conservation [3] - The association proposed a "three-party governance" approach involving consumers, content creators, and platform operators to foster a healthy online food environment [3] - This initiative reflects a strong sense of responsibility towards food security and social civility [3]

Market Overview - The Hong Kong stock market experienced a significant rise, with the Hang Seng Index increasing by 2.06%, the Hang Seng Tech Index by 2.14%, and the Hang Seng China Enterprises Index by 1.9% [2] - The technology, financial, and automotive sectors saw widespread gains, while oil and gas stocks faced substantial declines [2] Technology and Financial Stocks - Major technology and financial stocks rose, with Xiaomi increasing nearly 4%, Hongye Futures surging over 15%, and China Galaxy rising nearly 9% [3] - Leading insurance stocks included China Taiping and Ping An, while major banks like Bank of Communications, China Construction Bank, and Industrial and Commercial Bank of China reached new highs [3] Oil and Gas Sector - The oil and gas sector suffered due to a sharp decline in international oil prices, influenced by geopolitical developments in the Middle East [4] - Notable declines included United Energy Group falling over 21%, Sinopec Oilfield Services down 15.85%, and Dalip Holdings dropping over 10% [4][5] Automotive Sector - The automotive sector benefited from favorable market conditions, with significant gains in stocks such as BYD (up 3.25%), Li Auto (up 3.81%), and Leap Motor (up 4.34%) [6][7] - The China Association of Automobile Manufacturers reported that vehicle production and sales in the first five months of the year increased by over 10% year-on-year, with new energy vehicles showing particularly strong growth [8] Company-Specific Developments - Juzhibio saw a rise of 5.27% following a statement addressing the limitations of its current collagen product testing methods [9] - The company acknowledged the need for improved quality standards and testing methods in response to industry advancements and consumer expectations [11][13] - Future measures include collaborating with research institutions to enhance testing methods, publicly sharing key technical parameters, and participating in the formulation of national and industry standards [14]

Group 1: Market Overview - The Hong Kong stock market opened high and closed with significant gains, with the Hang Seng Index rising by 2.06%, the Hang Seng Tech Index by 2.14%, and the Hang Seng China Enterprises Index by 1.9% [2] - The technology and financial sectors saw widespread gains, while the oil and gas sector experienced a sharp decline [2][3] Group 2: Technology and Financial Stocks - Major technology and financial stocks rose, with Xiaomi increasing nearly 4%, Hongye Futures soaring over 15%, and China Galaxy rising nearly 9% [4] - Leading insurance stocks included China Taiping and Ping An, while major banks like CCB, ICBC, and CMB reached new highs [4][5] Group 3: Oil and Gas Sector - The oil and gas sector faced significant sell-offs due to a sharp drop in international oil prices, with companies like United Energy Group falling over 21% and Sinopec Oilfield Services down 15.85% [6][7] - Specific stock performances included China Petroleum down 0.30%, Sinopec Oilfield Services down 15.85%, and United Energy Group down 21.21% [8] Group 4: Automotive Sector - The automotive sector benefited from favorable market conditions, with stocks like BYD rising 3.25%, Li Auto up 3.81%, and Leap Motor increasing 4.34% [9][10] - The overall automotive industry showed positive growth, with production and sales in the first five months of the year increasing by over 10% year-on-year, and new energy vehicle sales reaching 44% of total new car sales [12] Group 5: Company-Specific News - Juzhibio saw a rise of 5.27% following a statement addressing the limitations of its current collagen product testing methods [13][14] - The company acknowledged the need for optimization in quality standards and testing methods to meet industry advancements and consumer expectations [18]

Group 1 - The core issue revolves around the dispute between two major players in the medical beauty industry, Juzi Biotechnology and Huaxi Biotechnology, regarding recombinant collagen products [2] - Juzi Biotechnology acknowledged limitations in its current quality standards, testing methods, and labeling, which are not fully aligned with the industry's evolving high standards and technological advancements [2][7] - Following the announcement, Juzi Biotechnology's stock price surged over 7% on June 24 [3] Group 2 - Juzi Biotechnology outlined three future initiatives: collaborating with research institutions to enhance testing methods for recombinant collagen in cosmetics, gradually disclosing key technical parameters and quality control data, and actively participating in the formulation of national and industry standards for recombinant collagen [7] - Huaxi Biotechnology previously addressed concerns about the lack of relevant testing standards in the recombinant collagen sector, emphasizing the misuse of the term "collagen" and the need for clear scientific conclusions to avoid misleading the market and consumers [10]

Core Viewpoint - The article discusses the ongoing dispute between two major players in the beauty industry, Juzi Biotechnology and Huaxi Biotechnology, focusing on Juzi's acknowledgment of limitations in their collagen product standards and their plans for improvement [2][8]. Group 1: Juzi Biotechnology's Response - Juzi Biotechnology admitted that their current quality standards, testing methods, and labeling have limitations that do not fully meet the high standards and requirements of industry development and technological advancement [2][8]. - The company plans to collaborate with research institutions to accelerate the optimization and validation of qualitative and quantitative testing methods for recombinant collagen in cosmetics [8]. - Juzi will gradually disclose key technical parameters and quality control data for raw materials and finished products to empower industry development and accept public supervision [8]. Group 2: Industry Standards and Developments - The latest industry standard for recombinant collagen dressings, YY/T 1947-2025, is set to be implemented in March 2026, indicating a need for updated compliance among companies [6]. - Juzi Biotechnology emphasized the necessity for continuous optimization and iteration of their quality standards and methods in response to the rapid development of the recombinant collagen industry and increasing consumer quality demands [8]. Group 3: Huaxi Biotechnology's Position - Huaxi Biotechnology previously addressed concerns regarding the lack of relevant testing standards in the recombinant collagen field, highlighting the misuse of the term "collagen" in the market [9]. - They criticized the misleading use of the term "collagen" by some companies, which do not produce the actual collagen sequence and structure, thus lacking physiological functionality [9]. - Huaxi believes that clear and scientifically verifiable conclusions are essential to avoid prolonged disputes and help companies resolve their issues quickly [9].